Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ORIC-944 + apalutamide
- Development stage
- Phase 1
- Lead developer
- ORIC Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ORIC-944 + apalutamide is an investigational combination therapy under clinical evaluation for metastatic castration-resistant prostate cancer (mCRPC). ORIC-944 is a potent, highly selective, allosteric, orally bioavailable small molecule inhibitor of the polycomb repressive complex 2 (PRC2), acting via the embryonic ectoderm development (EED) subunit. Apalutamide is a well-established androgen receptor (AR) inhibitor. This combination is designed to overcome resistance to AR pathway inhibition by simultaneously inhibiting PRC2-driven epigenetic mechanisms and directly blocking AR signaling. Early-phase clinical trials have demonstrated promising PSA response rates and a safety profile compatible with long-term dosing[1][2][5].
- Other names
- ORIC-944 + apalutamideErleada + ORIC-944
02
Targets
AR (Adrenergic receptors)EED (Embryonic ectoderm development protein)
Beyond the preview
Go deeper on ORIC-944 + apalutamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ORIC-944 + apalutamide.